Longevity & AgingAnnovis Bio Enrolls 850 Patients in Landmark Phase 3 Alzheimer's Drug Trial
Annovis Bio has finished enrolling 850 patients for a major Phase 3 trial of Buntanetap, an oral drug aimed at early Alzheimer's disease. Patients were confirmed to have Alzheimer's pathology using a blood biomarker called pTau217 and had mild cognitive impairment based on standard memory testing. The trial is randomized, placebo-controlled, and double-blind — the gold standard for clinical research. It will measure both short-term symptom relief at six months and longer-term disease modification at 18 months. If successful, the company plans to file for FDA approval. First results are expected in early 2027, making this one of the most closely watched Alzheimer's drug trials currently underway.
